Marble Harbor Investment Counsel LLC Has $790,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Marble Harbor Investment Counsel LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,480 shares of the medical instruments supplier’s stock after selling 363 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Becton, Dickinson and Company were worth $790,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $25,000. Sierra Ocean LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new stake in Becton, Dickinson and Company in the third quarter worth about $33,000. Tompkins Financial Corp increased its position in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Finally, Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company in the third quarter worth about $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on BDX shares. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Barclays lifted their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Stock Up 1.8 %

NYSE:BDX opened at $229.51 on Friday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock has a market cap of $65.90 billion, a price-to-earnings ratio of 38.12, a PEG ratio of 1.63 and a beta of 0.35. The stock has a 50-day moving average price of $232.98 and a two-hundred day moving average price of $232.73.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the sale, the executive vice president now owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,061 shares of company stock valued at $1,379,521 over the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.